

IN THE CLAIMS

1. (Currently Amended) A method for treating tumor diseases in which TRPM8 is overexpressed, comprising administration of a physiologically active dose of a pharmaceutical composition comprising ~~Use of a TRPM8-activating substance or mixtures containing a TRPM8-activating substance for the synthesis of a pharmaceutical composition for the treatment of tumor diseases in which TRPM8 is overexpressed.~~
2. (Currently Amended) The method of claim ~~Use as in Claim 1,~~ wherein the tumor disease is prostate cancer.
3. (Currently Amended) ~~Use of a substance, preferably as specified in Claims 1 or 2~~ The method of claim 1, wherein the substance that is selected from the group consisting of ~~[[“]]menthol, menthyl derivatives, pyrrolidinyl derivatives of furanone, icilin, icilin derivatives and mixtures of these substances[[”]] for the synthesis of a pharmaceutical composition for the treatment of tumor diseases, especially for the treatment of prostate cancer.~~
4. (Currently Amended) The method of claim 1, ~~Use as in one of Claims 1 through 3~~ wherein the substance or mixture of such substances is galenically prepared with ~~conventional accessories and carriers~~ additives comprising carriers, binding agents, coating agents, bursting agents, swelling agents, sliding agents, lubricants, flavoring substances, sweeteners or solution promoters.
5. (Currently Amended) ~~Pharmaceutical~~ A pharmaceutical composition for the treatment of tumor diseases ~~containing~~ comprising a TRPM8 activating substance ~~and/or~~ a substance that is selected from the group consisting of ~~[[“]]menthol, menthyl derivatives, pyrrolidinyl derivatives of furanone, icilin, icilin derivatives and mixtures of these substances, plus conventional accessories and carriers, preferably~~ and one or more

additives prepared galenically for intravenous, intraperitoneal or intramuscular injection ~~i.v., i.p., or i.m. or for~~ infusion.

6. (Currently Amended) ~~Pharmaceutical~~ The pharmaceutical composition as in ~~Claim of claim 5~~, in which the dose is set in the range from 0.1 to 1000 mg/kg body weight; ~~preferably 1 to 100 mg/kg body weight, relative to one~~ per day, divided into 1 to 10 dosage units.
7. (Currently Amended) ~~Pharmaceutical~~ The pharmaceutical composition as in ~~Claims 5 or 6 of claim 5~~, in which the composition is prepared for continuous or discontinuous periodical administration over a time interval of at least 2 weeks; ~~preferably at least 8 weeks.~~
8. (Currently Amended) ~~Process~~ A method for the treatment of tumor diseases, ~~especially comprising~~ prostate cancer, in which a patient suffering from the disease is given a physiologically active dose of a TRPM8-inhibiting substance, ~~especially comprising~~ a pharmaceutical composition according to one of claims ~~5 through 7~~ 5, 6, 7, 10 or 11.
9. (New) The method of claim 2, wherein the substance is selected from the group consisting of menthol, menthyl derivatives, pyrrolidinyl derivatives of furanone, icilin, icilin derivatives and mixtures of these substances.
10. (New) The pharmaceutical composition of claim 6, wherein the dosage is 1 to 100 mg/kg body weight per day, divided into 1 to 10 dosage units.
11. (New) The pharmaceutical composition of claim 6, wherein the composition is prepared for continuous or discontinuous periodical administration over a time interval of at least 2 weeks.
12. (New) The pharmaceutical composition of claim 7, wherein the time interval is at least 8 weeks.

13. (New) The pharmaceutical composition of claim 11, wherein the time interval is at least 8 weeks.
14. (New) The method of claim 1, wherein the tumor disease comprises neuroendocrine tumors comprising tumors of the gastrointestinal tract or respiratory organs.